Q/C TECHNOLOGIES, INC. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
On November 15, 2026, Q/C Technologies exchanged 851,304 Series G Long-Term Warrants held by PharmaCyte Biotech for 4,982,272 newly issued common shares. PharmaCyte, holding 3,000,000 Series H Preferred shares (majority), consented to extend the Series H Maturity Date from March 2, 2027 to September 2, 2027 (6-month extension). The share issuance triggers affiliate status for PharmaCyte and registration rights obligations for Q/C. No additional cash consideration was paid.
Why this rating
Major dilution event: 4.98M new shares issued against ~$3.6M market cap creates severe shareholder dilution. PharmaCyte gains control-level leverage (affiliate status + majority preferred holder + registration rights). Maturity extension avoids near-term preferred liquidation but signals refinancing pressure. Significant for cap structure and control, but not transformational—ordinary distressed restructuring for micro-cap.
Price action (we called it neutral)
at our read · unknown $0.28 | +10 min · unknown $0.31 ▲ 9.14% | +30 min · unknown $0.30 ▲ 6.76% | +1 hr · unknown $0.29 ▲ 4.23% | +4 hrs · unknown $0.31 ▲ 10.85% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.